10-K: Aspira Womens Health Faces Going Concern Doubt Amid Strategic Shift

Aspira Womens Health Inc. reported a net loss of $12.78 million for 2025, with substantial doubt about its ability to continue as a going concern, despite a strategic shift aimed at profitability.

Summary

• Incurred a net loss of $12.78 million for the fiscal year ended December 31, 2025, compared to $13.09 million in 2024.
• Experienced negative cash flows from operations of $7.03 million in 2025, an improvement from $12.11 million in 2024.
• Total product revenue remained materially unchanged at $9.22 million in 2025, despite a 7% reduction in unit sales (22,515 tests in 2025 vs. 24,305 in 2024).
• Average Unit Price (AUP) for OvaSuite increased to $409 in 2025 from $378 in 2024, driven by a focus on more profitable regions.
• Operating loss significantly reduced by 51% to $7.91 million in 2025 from $16.28 million in 2024.
• The ARPA-H contract for ENDOinform development, which provided $3.5 million in non-dilutive funding, was terminated in June 2025 due to failure to meet milestone specifications.
• Delisted from Nasdaq on April 15, 2025, and now trades on the OTC QX Best Market under the symbol AWHL.
• Accumulated deficit reached $544.18 million as of December 31, 2025, with a stockholders deficit of $6.93 million.
• Remediated a previously identified material weakness in internal control over financial reporting related to contract review processes and accounting for complex financial transactions.
• Launched a strategic shift in early 2025, reducing headcount from 66 to 36 full-time employees, reallocating sales resources, and optimizing marketing investments.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with a highly negative sentiment due to the explicit 'going concern' doubt, Nasdaq delisting, and the termination of a significant non-dilutive funding contract, overshadowing any operational improvements.

Positives

• Operating loss significantly reduced by 51% in 2025, demonstrating tangible progress toward profitability.
• Cash used in operations decreased by 40% in 2025, reflecting improved efficiency.
• Maintained flat revenue year-over-year despite a reduction in unit sales, achieved by focusing on higher-reimbursement opportunities and increasing Average Unit Price (AUP).
• Secured new channel partnerships with Mayo Clinical Laboratories and expanded collaboration with BioReference Health, LLC for Ova1 and OvaWatch distribution.
• Successfully expanded OvaWatch's mass monitoring feature in Q2 2024, completing the vision for OvaSuite and expanding the addressable market.
• Remediated a material weakness in internal control over financial reporting related to complex financial transactions.
• Published two peer-reviewed manuscripts in May 2024 supporting the utility of OvaWatch for surgical referral and longitudinal monitoring of adnexal masses.
• ACOG Practice Bulletin Number 174 (November 2016) recommends Ova1, achieving parity with CA-125 as a Level B clinical recommendation for adnexal mass management.
• CMS approved reimbursement for OvaWatch at $897 per test for Medicare patients, consistent with Ova1, effective January 1, 2024.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern due to significant losses and negative cash flows since inception, and expected net losses in 2026.
• The ARPA-H contract for ENDOinform development was terminated in June 2025, eliminating a planned source of non-dilutive funding ($6.5 million remaining) and potentially delaying commercialization.
• Delisted from Nasdaq on April 15, 2025, and now trades on the OTC QX Best Market, which may reduce liquidity and access to capital.
• Experienced a 7% reduction in OvaSuite unit sales in 2025 compared to 2024.
• Accumulated deficit of $544.18 million and stockholders deficit of $6.93 million as of December 31, 2025.
• Will need to sell additional shares or other securities in the future, which could cause significant dilution to stockholders.
• The current capital resources are not sufficient to fund operations for the remainder of 2026.
• The company's ability to utilize net operating loss carryforwards may be limited due to past and potential future ownership changes under Section 382 of the Internal Revenue Code.

Risks

• Inability to increase OvaSuite sales volume will adversely affect business, results of operations, and financial condition.
• Substantial doubt about the ability to continue as a going concern may adversely affect stock price and ability to raise capital.
• Need to sell additional shares or other securities in the future could cause significant dilution.
• Inability to secure adequate additional funds on acceptable terms may prevent execution of the business plan.
• Failures by third-party payers to reimburse for products or changes in reimbursement rates could materially and adversely affect business.
• Failure to continue coverage of Ova1 through Novitas, the Medicare Administrative Contractor, could materially and adversely affect business.
• Failure to expand commercial, Medicare, or Medicaid coverage for products could materially and adversely affect business.
• May not succeed in improving existing or developing additional diagnostic products, or they may not achieve significant commercial market acceptance.
• The diagnostics market is competitive, and inability to compete successfully would adversely impact revenue generation.
• Potential for FDA to actively regulate Laboratory Developed Tests (LDTs) could incur substantial costs and delays.
• Failure to comply with applicable FDA regulations for current and future FDA-regulated products could adversely affect business.
• Failure of suppliers to produce acceptable or sufficient stock, or changes/discontinuation of kits/platforms, could prevent meeting market demand.
• Changes in healthcare policy could increase costs and adversely impact sales and reimbursement.
• Subject to environmental laws and potential exposure to environmental liabilities.
• Operation of Aspira Labs requires compliance with numerous laws and regulations, which is expensive and time-consuming, and failure to comply could result in substantial penalties.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited.
• If the ARPA-H award is reinstated, inability to complete required milestones would adversely affect business.
• Failure to renew the Quest Diagnostics agreement could impact business.
• Failure to maintain rights to utilize intellectual property directed to diagnostic biomarkers may prevent offering diagnostic tests.
• Third-party infringement on proprietary rights could lead to competitive disadvantage, diversion of time, and enforcement costs.
• Successful assertion of proprietary rights by others against the company may preclude making/selling products or require obtaining licenses.
• Significant product liability exposure from testing, manufacturing, and marketing medical diagnostic tests.
• Expiration of certain patent registrations may cause significant competition.
• Inability to recruit and retain key executives and employees could hinder business plans.
• Business interruptions (e.g., natural disasters, cyber-attacks) could limit ability to operate.
• Compromise of information technology systems or data could lead to adverse consequences.
• Inability to successfully integrate acquired businesses, products, or technologies, or strategic alliances, may not produce anticipated results.
• Future litigation could be costly and time-consuming.
• Limited market for common stock and potential removal to OTC QB market if OTC QX minimum listing requirements are not met.
• Low liquidity and trading volume of common stock, and concentrated ownership, could adversely impact trading price.
• Stock price has been, and may continue to be, highly volatile.
• Anti-takeover provisions in charter, bylaws, other agreements, and Delaware law could make a third-party acquisition difficult.
• Future capital raises could dilute ownership.
• Sales of a substantial number of common stock shares in the public market could cause stock price to fall.
• Stockholders must rely on appreciation of common stock value for return on investment, as no cash dividends are intended.
• Exercise of outstanding options and warrants will dilute stockholders and could decrease stock price.

Future Outlook

Aspira Womens Health plans to broaden its commercial focus from ovarian cancer to a range of gynecological diseases, including endometriosis and benign pelvic mass monitoring. The company expects to continue commercializing existing and new technology through in-house and distributed pathways, aiming to expand access to tests among Medicaid patients and advocate for legislation. Research and development expenses are expected to increase in 2026 due to pipeline focus, while sales, marketing, and general and administrative expenses are expected to remain flat. The company anticipates incurring a net loss and negative cash flows from operations in 2026 and will require additional capital to fund operations and product pipeline development.

Management Comments

• "We plan to broaden our commercial focus from ovarian cancer to differential diagnosis of women with a range of gynecological diseases, including additional pelvic disease conditions such as endometriosis and benign pelvic mass monitoring."
• "We expect our extensive experience with gynecologists and healthcare providers, along with the historical adoption of our OvaSuite tests, to continue to drive growth as we introduce new products."
• "We believe our ability to successfully develop novel AI-enabled assays is superior to others based on our know-how and extensive experience in designing and successfully launching FDA-approved and laboratory developed blood tests to aid in the diagnosis of ovarian cancer."
• "Our current capital resources are not sufficient to fund our operations for the remainder of 2026. Accordingly, we have been pursuing strategic alternatives and seeking to raise additional capital."
• "Management will continue to execute on these initiatives, with a focus on cost efficiency, improved average unit pricing for its tests, and increased unit sales. In 2026, we plan to build on this momentum as we advance our path to profitability and achieve key milestones across our product pipeline."
• "We disagree with this finding and believe we have successfully completed the third milestone per the agreement. After the termination of this award, we have continued to fund ENDOinform development work."

Industry Context

StockSavvy.ai notes that Aspira Womens Health operates in a competitive and evolving diagnostics industry, with a strategic focus on gynecologic oncology and disease, an area generally lacking quality diagnostic tests. The company's emphasis on AI-powered, multi-marker tests aligns with broader industry trends towards advanced diagnostics and personalized medicine. The termination of the ARPA-H contract highlights the challenges in securing non-dilutive government funding for innovative health solutions, while the ongoing debate around FDA regulation of LDTs (as seen with the VALID Act) indicates a dynamic regulatory landscape that could impact all players in the diagnostic space. The entry of large players like Exact Sciences and Grail into multi-cancer early detection (MCED) tests, including ovarian cancer, signals increasing competition and the need for specialized companies like Aspira to differentiate through superior sensitivity and specificity.

Comparison to Industry Standards

• Aspira's Ova1 test achieved parity with CA-125 as an ACOG Level B clinical recommendation for adnexal mass management, indicating recognition within professional guidelines.
• Studies in 2013 and 2019 suggest Ova1 has superior sensitivity compared to Fujirebio Diagnostics' ROMA test, a direct competitor in ovarian cancer risk assessment.
• The company's focus on multi-marker tests combining serum proteins, miRNA, and clinical data aims to improve accuracy, sensitivity, and specificity over conventional single-biomarker tests like CA-125, which is known for its limitations in early-stage ovarian cancer detection and specificity.
• The addressable market for OvaSuite tests (2-4 million per year) and the expanded OVAinform indication (totaling 4 million women) positions Aspira in significant market segments, though actual market penetration and revenue generation remain a challenge given current sales volumes.
• The delisting from Nasdaq to OTC QX Best Market places Aspira in a less liquid and less visible market compared to industry peers listed on national exchanges, potentially hindering capital access and investor interest.

Corporate Governance

Legal Proceedings

• The company is from time to time subject to legal proceedings and regulatory proceedings arising out of its operations, but as of the filing date, is not a party to any proceeding whose adverse outcome would have a material adverse effect on its financial position or results of operations.

Related Party Transactions

• Entered into a consulting agreement with Biodesix, Inc. on December 1, 2023, to assist with the miRNA product pipeline. Jack Schuler, a beneficial owner of more than 10% of Aspira's stock, is also a beneficial owner of more than 10% of Biodesix, Inc. Costs incurred under this agreement were $125,000 as research and development expense.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future capital raises and potential loss of investment due to going concern doubt and delisting from Nasdaq. Concentrated ownership may limit influence of other stockholders.
• **Employees:** Headcount reduction from 66 to 36 full-time employees in early 2025 indicates job insecurity and potential impact on morale.
• **Customers (Physicians/Patients):** Continued availability of OvaSuite tests and development of new diagnostics like ENDOinform and OVAinform offer potential benefits for gynecologic disease diagnosis and management, but financial instability could pose long-term risks to product availability and support.
• **Suppliers/Creditors:** The going concern doubt and need for additional financing could raise concerns about the company's ability to meet future obligations, potentially impacting terms of agreements.
• **Regulatory Bodies:** The company's compliance with FDA and CLIA regulations is critical for operations, and any failures could lead to sanctions, impacting product availability.

Next Steps

• Raise additional capital through public or private equity offerings, debt financing, collaborations, licensing arrangements, grants, and government funding, or strategic alliances.
• Continue sales and marketing efforts for ovarian cancer and endometriosis offerings.
• Continue developing the product pipeline and service capabilities, including ENDOinform and OVAinform.
• Endeavor to reinstate the terminated ARPA-H award or secure alternative financing for ENDOinform development.
• Negotiate a renewal agreement with Quest Diagnostics for U.S. testing services.
• Work with Mayo sales team to collaborate and co-market to Mayo clients beginning in 2026.
• Continue to build clinical evidence to support coverage and reimbursement for OvaWatch.
• Monitor developments regarding FDA interpretation of the court ruling on LDTs and potential new regulatory approaches.
• Continue to advocate for legislation and professional society guidelines to broaden access to products and services.

Key Dates

Recommendation

Aspira Womens Health Inc. explicitly states 'substantial doubt about our ability to continue as a going concern,' which is a critical red flag for investors. The company's delisting from Nasdaq to the OTC QX market severely limits liquidity and institutional interest. While management has implemented a strategic shift to reduce cash burn and improve profitability, the financial results for 2025 still show a net loss and negative cash flow from operations, and the loss of the ARPA-H contract is a significant blow to non-dilutive funding. The ongoing need for substantial capital raises, coupled with the risk of significant dilution and the highly volatile stock price, presents an extremely high-risk investment profile. A seasoned investor would likely view the fundamental risks as outweighing any potential future upside, making a 'strong sell' recommendation appropriate to mitigate further capital loss.

Keywords

Ovarian Cancer Diagnostics, Endometriosis Diagnostics, AI-powered Tests, Gynecologic Diseases, OvaSuite, Ova1Plus, OvaWatch, ENDOinform, OVAinform, SEC Filing, 10-K, Financial Reporting, Going Concern, Nasdaq Delisting, OTC QX Market, Biomarkers, LDTs, FDA Regulation, Reimbursement, Capital Raise, Clinical Laboratory, CLIA, Medical Devices